MYC dysregulation in the progression of multiple myeloma

Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study

Landgren, O., Kyle, R. A., Pfeiffer, R. M., Katzmann, J. A., Caporaso, N. E., Hayes, R. B., Dispenzieri, A., Kumar, S., Clark, R. J., Baris, D., et al. (2009) · Blood · doi:10.1182/blood-2008-12-194241 · Cited by 1,127

Multiple myeloma: evolving genetic events and host interactions

Kuehl, W. M., & Bergsagel, P. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc746 · Cited by 818

Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma

Bergsagel, P. L., Kuehl, W. M., Zhan, F., Sawyer, J. R., Barlogie, B., & Shaughnessy, J. D. (2005) · Blood · doi:10.1182/blood-2005-01-0034 · Cited by 700

A monoclonal gammopathy precedes multiple myeloma in most patients

Weiss, B. M., Abadie, J. M., Verma, P. S., Howard, R. S., & Kuehl, W. M. (2009) · Blood · doi:10.1182/blood-2008-12-195008 · Cited by 568

MYC Deregulation in Primary Human Cancers

Kalkat, M., Melo, J. D., Hickman, K. A., Lourenco, C., Redel, C., Resetca, D., Tamachi, A., Tu, W. B., & Penn, L. Z. (2017) · Genes · doi:10.3390/genes8060151 · Cited by 469

Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma

Affer, M., Chesi, M., Chen, W. D., Keats, J. J., Demchenko, Y. N., Tamizhmani, K., Garbitt, V. M., Riggs, D. L., Brents, L. A., Roschke, A. V., et al. (2014) · Leukemia · doi:10.1038/leu.2014.70 · Cited by 273

Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients

Walker, B. A., Wardell, C. P., Brioli, A., Boyle, E. M., Kaiser, M., Begum, D. B., Dahir, N. B., Johnson, D. C., Ross, F. M., Davies, F. E., et al. (2014) · Blood Cancer Journal · doi:10.1038/bcj.2014.13 · Cited by 182

MAX Inactivation in Small Cell Lung Cancer Disrupts MYC–SWI/SNF Programs and Is Synthetic Lethal with BRG1

Romero, O. A., Torres-Diz, M., Pros, E., Savola, S. P., Gómez, A., Morán, S., Sáez, C., Iwakawa, R., Villanueva, A., Montuenga, L. M., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0799 · Cited by 164

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis

Barwick, B. G., Neri, P. E., Bahlis, N. J., Nooka, A. K., Dhodapkar, M. V., Jaye, D. L., Hofmeister, C. C., Kaufman, J. L., Gupta, V. A., Auclair, D., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09555-6 · Cited by 147

Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability

Dutta, A. K., Fink, J. L., Grady, J. P., Morgan, G. J., Mullighan, C. G., To, L. B., Hewett, D. R., & Zannettino, A. C. W. (2018) · Leukemia · doi:10.1038/s41375-018-0206-x · Cited by 140

Increased complexity of t(11;14) rearrangements in plasma cell neoplasms compared with mantle cell lymphoma

Dalland, J., Smadbeck, J. B., Sharma, N., Meyer, R. G., Pearce, K. E., Greipp, P. T., Peterson, J. F., Kumar, S. K., Ketterling, R. P., King, R. L., et al. (2021) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22977 · Cited by 7

Cytogenetics in the management of multiple Myeloma: The guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH)

Daudignon, A., Cuccuini, W., Bracquemart, C., Godon, C., Quilichini, B., & Penther, D. (2023) · Current Research in Translational Medicine · doi:10.1016/j.retram.2023.103427 · Cited by 7

Diagnosis, risk stratification and management of smouldering multiple myeloma

Zanwar, S., Kumar, S. K., & Rajkumar, S. V. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01119-0 · Cited by 6

Progression of monoclonal gammopathy of undetermined significance to multiple myeloma is associated with enhanced translational quality control and overall loss of surface antigens

Berg, S. R., Dikic, A., Sharma, A., Hagen, L., Vågbø, C. B., Zatula, A., Misund, K., Waage, A., & Slupphaug, G. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05345-x · Cited by 8

Disease heterogeneity, prognostication and the role of targeted therapy in multiple myeloma

Zanwar, S., & Kumar, S. K. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1957875 · Cited by 6

China's potential role in humanitarian assistance

Binder, A., & Conrad, B. (2009) · Cited by 6

Mitochondrial dysfunction and drug targets in multiple myeloma

Cui, Y., Wang, F., & Fang, B. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04672-8 · Cited by 6

Molecular genetic aberrations in the pathogenesis of multiple myeloma

Bong, I. P. N., & Esa, E. (2023) · Asian Biomedicine · doi:10.2478/abm-2023-0056 · Cited by 5

RECENT ADVANCES IN THE DEFINITION OF THE MOLECULAR ALTERATIONS OCCURRING IN MULTIPLE MYELOMA

Testa, U., Pelosi, E., Castelli, G., & Leone, G. G. M. (2024) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2024.062 · Cited by 5

Inhibition of FOXM1 Synergizes with BH3 Mimetics Venetoclax and Sonrotoclax in Killing Multiple Myeloma Cells through Repressing MYC Pathway

Wen, Z. H., Wang, Y., Fox, K. C., Bissonnette, A. M., Moat, L. F., Kitchner, T., Springstroh, K., Kim, S. H., Sheerar, D. S., Tanawattanacharoen, P., et al. (2025) · Advanced Science · doi:10.1002/advs.202508822 · Cited by 5

Myc rearrangement redefines the stratification of high‐risk multiple myeloma

Jin, X., Li, H. Y., Zhang, D., Liu, S., Song, Y., Zhang, F., Li, Z., & Zhuang, J. (2024) · Cancer Medicine · doi:10.1002/cam4.7194 · Cited by 5

Progress in the Management of Smoldering Multiple Myeloma

Schmidt, T. M., & Callander, N. S. (2021) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-021-00623-7 · Cited by 6

Targeting the tumor and the immune system in smoldering multiple myeloma

Maura, F., & Bergsagel, P. L. (2025) · New England Journal of Medicine · doi:10.1056/nejme2504273 · Cited by 5

Robust anti-myeloma effect of TAS0612, an RSK/AKT/S6K inhibitor, with venetoclax regardless of cytogenetic abnormalities

Okamoto, H., Mizutani, S., Tsukamoto, T., Katsuragawa‐Taminishi, Y., Kawaji‐Kanayama, Y., Mizuhara, K., Muramatsu, A., Isa, R., Fujino, T., Shimura, Y., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02439-9 · Cited by 5

Prognostic role of TNF alpha, LT alpha, MDR1 and codon 72 Tp53 gene polymorphisms on multiple myeloma Egyptian patients

Hegazi, H. M., El-Ghonemy, M. S., El-Baiomy, M., Soliman, E. A., & Abdel‐Hady, E. K. (2022) · Leukemia Research · doi:10.1016/j.leukres.2022.106854 · Cited by 4

Differential diagnosis of multiple myeloma

Cantu, M. D., & Chen, W. (2025) · Seminars in Diagnostic Pathology · doi:10.1016/j.semdp.2025.150944 · Cited by 3

Immunocompetent Mouse Models of Multiple Myeloma

Du, M. T., Bergsagel, P. L., & Chesi, M. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.12.014 · Cited by 3

NT157 exhibits antineoplastic effects by targeting IRS and STAT3/5 signaling in multiple myeloma

de Queiroz, G. N., Lima, K., de Miranda, L. B. L., Rego, E. M., Traina, F., & Machado‐Neto, J. A. (2024) · Hematology Transfusion and Cell Therapy · doi:10.1016/j.htct.2024.02.017 · Cited by 3

Mouse tumor susceptibility genes identify drug combinations for multiple myeloma

Zhang, S., Dubois, W., Zhang, K., Simmons, J. K., Hughitt, V. K., Gorjifard, S., Gaikwad, S. M., Peat, T. J., & Mock, B. A. (2020) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2020.40 · Cited by 3

Multiple Myeloma With Amplification of Chr1q: Therapeutic Opportunity and Challenges

Sklavenitis‐Pistofidis, R., Getz, G. A., Ghobrial, I. M., & Papaioannou, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.961421 · Cited by 3

Molecular Diagnostics of Plasma Cell Neoplasms

Fitzpatrick, M. J., Murali, M. R., & Nardi, V. (2023) · Surgical pathology clinics · doi:10.1016/j.path.2023.01.005 · Cited by 3

Survival Genie 2: a next-generation web server for targeted and single-cell-based survival analyses

Huang, C., Michaud, M. E., Mumme, H., Bhasin, S. S., & Bhasin, M. (2026) · Genome Medicine · doi:10.1186/s13073-026-01651-9 · Cited by 2

Approach to High-Risk Multiple Myeloma

Chen, X., Varma, G., Davies, F. E., & Morgan, G. J. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.12.008 · Cited by 2

Hyperdiploid myeloma: The silent majority

Wiedmeier, J. E., & Fonseca, R. (2025) · British Journal of Haematology · doi:10.1111/bjh.20190 · Cited by 2

YAP Upregulation Contributes to Acquired Resistance to BET Inhibitors in Uveal Melanoma

Zhou, Y., Liu, X., Huang, S., Zhang, G., Jin, X., Chen, L., Yu, L., & Li, Y. (2025) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.70036 · Cited by 2

LncRNAs: Novel therapeutic targets to treat Multiple Myeloma with RNA-based therapies

Amundarain, A. (2023) · Deposito Adademico Digital Universidad De Navarra (University of Navarra) · doi:10.15581/10171/67866 · Cited by 2

Lymphoma-like double-hit genetic abnormalities (MYC/IGH and IGH/BCL2) in a case of non-secretory multiple myeloma

Kaya, E. A., Baughn, L. B., Pham, T. T., Ketterling, R. P., Kumar, S. K., & Jevremović, D. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1821012 · Cited by 1

A Novel Integrated Approach for Cytogenomic Evaluation of Plasma Cell Neoplasms

Aarabi, M., Yoest, J. M., Farah, R., Rajkovic, A., Swerdlow, S. H., & Yatsenko, S. A. (2022) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2022.07.002 · Cited by 1

BDL-SP: A Bio-inspired DL model for the identification of altered Signaling Pathways in Multiple Myeloma using WES data.

Ruhela, V., Jena, L., Kaur, G., Gupta, R., & Gupta, A. (2023) · PubMed Central · Cited by 1

What Is Genomic High-Risk Myeloma?

Davies, F. E., & Walker, B. A. (2022) · Hemato · doi:10.3390/hemato3020021 · Cited by 1

Molecular Profiling and Minimal Residual Disease Monitoring in Multiple Myeloma Patients: A Literature Review

Semyanikhina, A. V., & Tolstykh, E. E. (2021) · Clinical oncohematology · doi:10.21320/2500-2139-2021-14-4-436-443

Leukemias, Lymphomas, and Plasma Cell Disorders

Morrissette, J. J. D., Roth, J. J., Luger, S. M., & Stadtmauer, E. A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-812534-2.00012-6

Identification of novel long noncoding RNA with distinct expression patterns in different subtypes of multiple myelomaPreprint

Elsayed, D., Ashby, C., Wardell, C. P., van Rhee, F., Ussery, D. W., Zhan, F., & Bauer, M. (2022) · Research Square · doi:10.21203/rs.3.rs-1954260/v1

Data from Designing Evolutionary-based Interception Strategies to Block the Transition from Precursor Phases to Multiple Myeloma

Maura, F., Landgren, O., & Morgan, G. J. (2023) · doi:10.1158/1078-0432.c.6530273

Data from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma

Termini, R., Žihala, D., Terpos, E., Pérez-Montaña, A., Jelı́nek, T., Raab, M. S., Weinhold, N., Mai, E. K., Grab, A. L., Corre, J., et al. (2023) · doi:10.1158/1078-0432.c.6532880

Data from Designing Evolutionary-based Interception Strategies to Block the Transition from Precursor Phases to Multiple Myeloma

Maura, F., Landgren, O., & Morgan, G. J. (2023) · doi:10.1158/1078-0432.c.6530273.v1

The Age of Immune-therapy in Multiple Myeloma with a Collective Goal for a Cure

Larios, J. M., & Terebelo, H. R. (2023) · Medical Research Archives · doi:10.18103/mra.v11i10.4607

Dedication

Bergsagel, P. L. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2024.01.002

Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

Etxebeste, A. (2023) · Deposito Adademico Digital Universidad De Navarra (University of Navarra) · doi:10.15581/10171/69185

The molecular biology of multiple myeloma

Yadav, U., & Gonsalves, W. I. (2024) · Wiley eBooks · doi:10.1002/9781394180486.ch10

Inhibition of FOXM1 synergizes with BCL2 inhibitor Venetoclax in killing non-t(11;14) multiple myeloma cells via repressing MYC pathwayPreprint

Wen, Z. H., Janz, S., Wang, Y., Katzenellenbogen, B. S., Katzenellenbogen, J. A., Kim, S. H., & Onitilo, A. A. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.27.613548

Mer receptor expression promotes multiple myeloma disease development via a cell-extrinsic mechanism

Clark, J. R., Panagopoulos, V., Noll, J. E., Mrozik, K. M., Bradey, A. L., Croucher, P. I., Zannettino, A. C. W., Vandyke, K., & Hewett, D. R. (2025) · Experimental Hematology · doi:10.1016/j.exphem.2025.104842

Association Between Patient Demographics and Smoldering Multiple Myeloma Progression to Multiple Myeloma: A SEER-Medicare Data Analysis

Theprungsirikul, P. P., Wang, R., Ahmad, I., Neparidze, N., Ma, X., Chang, S., & Wang, S. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.06.016

Additional file 1 of WDR26 and MTF2 are therapeutic targets in multiple myeloma

Sun, F., Cheng, Y., Riordan, J. D., Dupuy, A. J., Dubois, W., Pisano, M. D., Dong, J., Mock, B., Zhan, F., Hari, P., et al. (2021) · Figshare · doi:10.6084/m9.figshare.17141203

The genetic architecture of plasma cell disorders

Boyle, E. M. (2020) · theses.fr (ABES) · doi:10.70675/404c872dz0ef2z4f8eza81fz592360ed443b

Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study

Nadeem, O., Aranha, M. P., Redd, R. A., Koontz, M. Z., Matous, J. V., Yee, A. J., Zonder, J. A., Kin, A. D., Magidson, S., Lightbody, E. D., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-71483-z

Dissecting the role of long non-coding RNA in multiple myeloma

Zocchi, S. (2024) · theses.fr (ABES) · doi:10.70675/22f35f26z6442z47d6z8cdaz153527b5df6e

Smoldering Multiple Myeloma: From Clinical to Immunogenomic Risk Stratification and Therapeutic Implications of Early Intervention

Bahlis, N. J., Mateos, M. V., & Nooka, A. K. (2026) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-26-517488

Continuous multi-omics pathway enrichment analysis resolves hidden functional heterogeneity

AmeriFar, S., Kopf, A., Sass, S., Moslehi, Z., Hecker, D., Enssle, J. C., Schulz, M. H., Oellerich, T., Theis, F. J., & Buettner, F. (2026) · Briefings in Bioinformatics · doi:10.1093/bib/bbag328

Multiple myeloma: A tale of deregulated transcription factors

Gómez-Echarte, N., José‐Eneriz, E. S., Compains, E., Rodríguez‐Otero, P., Prósper, F., & Agirre, X. (2026) · HemaSphere · doi:10.1002/hem3.70411

Establishment and characterization of multiple myeloma cell lines from a single patient’s disease course immortalizes clonal heterogeneity

Wiedmeier, J. E., Riggs, D., Stein, C., Mangalaparthi, K. K., Kandasamy, R. K., Brown, S., Franke, K., Shotts, Y., Aguirre, J. F., Asmann, Y. W., et al. (2026) · Blood Cancer Journal · doi:10.1038/s41408-026-01597-6

Xuanbi Xiaoliu formula alleviates bone destruction by targeting the CREBBP/c-Myc axis with saponarin in multiple myeloma

Qian, J., Zhang, J., Deng, Z., 戈小洁, Wang, C., Sun, S., Yu, X., Wu, H., Kong, X., Wei, J., et al. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.158783

The NSDHL/c-Myc/PKM2 Axis Drives Glycolytic Reprogramming and Tumor Growth in Multiple Myeloma

Yue, C., Huang, B.-H., Qi, L., Zhang, X., & Li, J. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188239

Hyperdiploid multiple myeloma: A heterogeneous entity requiring refined risk stratification—Insights from chromosome count and cytogenetic abnormalities

Zeng, Z., Lu, J., Shang, J., 游, 鸿., Wang, Q., Wen, L., Wang, Q., Yan, W., Wu, C., Wang, P., et al. (2026) · British Journal of Haematology · doi:10.1111/bjh.70817

Pathogenic mechanisms and targeted therapeutic advances of the FGF/FGFR signaling pathway in hematological malignancies

Xiulan, L. O. U., ZHENG, Z., & Xiaokun, L. I. (2026) · Journal of Zhejiang University (Medical Sciences) · doi:10.3724/zdxbyxb-2026-0286

MicroRNA signatures characterize multiple myeloma patients

Corthals, S. L., Sun, S. M., Kuiper, R., de Knegt, Y., Broyl, A., van der Holt, B., Beverloo, H. B., Peeters, J. K., el Jarari, L., Lokhorst, H. M., et al. (2011) · Leukemia · doi:10.1038/leu.2011.147 · Cited by 56

Single cell characterization of myeloma and its precursor conditions reveals transcriptional signatures of early tumorigenesis

Boiarsky, R. P., Haradhvala, N. J., Alberge, J.-B., Sklavenitis‐Pistofidis, R., Mouhieddine, T. H., Zavidij, O., Shih, M., Firer, D. T., Miller, M. L., El‐Khoury, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33944-z · Cited by 80

Glycosylation Single-Cell Transcriptomic Profiling Decodes Driver Mechanism and Genetic Characteristics of Circulating Plasma Cells in Multiple Myeloma

Qu, X., Sun, Z., Li, Y., Ying, W., Liu, Y., Wang, C., Hu, N., Tohetuoxun, S., Tong, D., Liu, H., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/s2152-2650(25)04020-0

Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease

Dang, M., Han, G., Lee, H. C., Patel, K. K., Becnel, M. R., Wang, R., Thomas, S. K., Hao, D., Chu, Y., Weber, D. M., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.05.007 · Cited by 55

Single-cell analysis unveils distinct transcriptional alterations and cellular origins in IgD multiple myeloma

Luo, T., Zhou, X., Chen, X., Jin, L., Yang, Y., Hu, X., Li, J., & Du, J. (2025) · Haematologica · doi:10.3324/haematol.2025.288418